Peptide Health Lab

Repair & recovery

KPV

FOR RESEARCH PURPOSES ONLY

Also known as: Lys-Pro-Val, alpha-MSH 11-13, KPV tripeptide

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed August 2, 2026 · 11 sources

What KPV is and how it works

KPV is three amino acids: lysine, proline, valine. That is the entire molecule.

It is the carboxy-terminal tripeptide of alpha-melanocyte-stimulating hormone, a thirteen-amino-acid peptide derived from proopiomelanocortin whose full sequence is SYSMEHFRWGKPV; KPV is residues 11 through 13.[1] Alpha-MSH has been studied for decades as an endogenous anti-inflammatory signal, with effects on nuclear factor-kappaB activation, adhesion molecule and chemokine receptor expression, pro-inflammatory cytokine production, interleukin-10 synthesis, T cell proliferation, and inflammatory cell migration, validated across animal models of fever, contact dermatitis, vasculitis, fibrosis, ocular and brain inflammation, gut inflammation, and arthritis.[6]

The reason anyone bothered to isolate the last three residues is specific and worth knowing: alpha-MSH also causes pigmentation, and that pigmentary effect is the obstacle to using it as an anti-inflammatory drug. Reviewers describe the C-terminal tripeptide as retaining the anti-inflammatory activity while lacking the pigmentary action, which is what put KPV forward as the developable alternative.[6][3]

The mechanism that distinguishes KPV from most research peptides is its transporter. KPV enters cells through PepT1, a di/tripeptide transporter that is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease. Uptake was demonstrated with radiolabelled peptide and competition experiments in human intestinal epithelial cell lines and in T cells, and the anti-inflammatory effect tracked PepT1 expression.[4] That gives the compound an unusually clean story: the transporter that carries it is upregulated precisely where the inflammation is.

Downstream, nanomolar concentrations inhibited NF-kappaB and MAP kinase inflammatory signalling and reduced pro-inflammatory cytokine secretion in those cells.[4] Whether melanocortin receptors are involved is less settled. See below.

What the research actually shows

Rodent colitis is the deep end of the literature, and it replicates. In the foundational study, oral KPV in drinking water reduced the incidence of both dextran-sodium-sulfate and TNBS-induced colitis in mice, with decreased pro-inflammatory cytokine mRNA expression and improvement at the histological level.[4] An independent group, working in Münster rather than Atlanta, reported that KPV treatment in DSS colitis produced earlier recovery and significantly stronger regain of body weight, significantly reduced inflammatory infiltrates on histology, and significantly reduced colonic myeloperoxidase activity; the same effects appeared in CD45RB-high transfer colitis.[5] A later rat study using a cysteamine-grafted polyglutamic acid hydrogel to stabilize the peptide reported the same direction of effect in TNBS colitis.[10] Independent replication across groups and models is rarer in this category than the marketing suggests, and KPV genuinely has it. In rodents.

Receptor independence. Mice expressing a nonfunctional melanocortin-1 receptor were still rescued by KPV during DSS colitis, which argues the anti-inflammatory effect is at least partly independent of MC1R signalling.[5] Human keratinocyte work complicates the picture further: neither alpha-MSH nor KPV elevated cyclic AMP in HaCaT or normal keratinocytes, but both produced rapid intracellular calcium responses under conditions where the cyclic AMP pathway was inhibited, and MC1-receptor-transfected cells responded to the tripeptides.[2] The honest summary is that KPV does something reproducible and that the receptor-level account is unfinished.

Colitis-associated cancer. In an AOM/DSS mouse model, PepT1 was shown to play a critical role in promoting colitis-associated cancer, and KPV delivered via that transporter produced therapeutic benefit in the same model.[8]

Formulation. Much of the last decade of work is delivery engineering. Hyaluronic-acid-functionalized polymeric nanoparticles loaded with KPV, sized around 272 nm and encapsulated in a chitosan/alginate hydrogel, targeted colonic epithelial cells and macrophages, accelerated mucosal healing, downregulated TNF-alpha, and outperformed untargeted KPV nanoparticles in a mouse ulcerative colitis model.[9]

Antimicrobial activity. alpha-MSH peptides including KPV inhibited Staphylococcus aureus colony formation and reduced viability and germ tube formation of Candida albicans in culture, across a broad concentration range including picomolar, with cyclic AMP implicated in the killing activity.[1]

Where the evidence is weak

There is no human evidence at all. Not a randomized trial, not an open-label series, not a case report worth citing. Reviews from 2008, 2010, and 2023 all describe the melanocortin tripeptides as promising candidates for future development of treatments for immune-mediated inflammatory disease.[6][7][11] Fifteen years of "future" is data of a kind. Whatever obstacles sit between a compelling mouse colitis result and a clinical programme, they have not been cleared.

The delivery problem is unsolved and load-bearing. Multiple groups built targeted nanoparticle and hydrogel carriers specifically because free KPV does not reach inflamed intestinal tissue efficiently.[9][10] The most impressive published results belong to engineered formulations rather than to the peptide as such. That is exactly the gap between the literature and any unformulated research material.

The gut results are gut results. The mechanism is transporter-dependent and the transporter is induced in inflamed intestine.[4] That is a strong argument for intestinal inflammation and a weak one for any claim outside the gut. Skin and wound applications rest on cell-culture calcium signalling and on inference from the parent hormone.[2]

The mechanism is immunosuppression. Inhibiting NF-kappaB, MAP kinase signalling, adhesion molecules, and cytokine production is the intended effect.[7] No study has examined what sustained exposure does to infection risk or immune surveillance in a person, and the antimicrobial activity reported in vitro raises an unanswered question about the intestinal microbiome.[1]

The transporter has a second story. PepT1 promotes colitis-associated cancer in mice.[8] The paper frames KPV as the therapeutic counterweight, and that is a fair reading of its data. It also means the biological neighbourhood this peptide lives in is more complicated than a one-line anti-inflammatory description implies.

Long-term safety is unknown. Rodent colitis studies run days to weeks. Nothing published speaks to prolonged exposure in humans.

Legal and regulatory status

KPV is not approved by the FDA for any indication, and it is not approved by other major regulators. It is not an approved drug and it is not a characterized dietary ingredient; material labeled KPV is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing.

Unlike some compounds in this category, KPV has no history of a completed pharmaceutical development programme. Reviews continue to position it as a candidate whose physicochemical properties and expected low production cost make it suitable for development in inflammatory skin and bowel disease, fibrosis, allergic and inflammatory lung disease, ocular inflammation, and arthritis.[6] The 2023 review of the melanocortin system in inflammatory bowel disease reaches a similar conclusion: molecules interfering with this system could represent new drugs for treating IBD. That is a forward-looking statement about a research field.[11] The parent hormone alpha-MSH is likewise not an approved anti-inflammatory therapy.

PHL does not sell peptides, does not tell anyone how to obtain them, and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything labeled KPV.

Questions to bring to a provider

For most readers arriving here, the underlying question is a gut or skin inflammation problem with a real diagnosis attached to it. That diagnosis, not the peptide, is where a useful conversation starts. Questions worth raising:

  • What is the actual diagnosis, and what does the standard-of-care evidence base offer for it? Inflammatory bowel disease in particular has approved therapies with randomized trial evidence behind them.
  • Given that the entire efficacy literature for this compound is rodent and cell work, and that the strongest results used engineered delivery systems rather than free peptide, what would have to be true for it to be worth considering at all?[9]
  • If the mechanism is inhibition of inflammatory signalling, what does that mean alongside current immunosuppressive or biologic therapy?[7]
  • Does a history of colorectal dysplasia, colitis-associated cancer risk, or active infection change the calculus?[8]
  • Which objective measures would be followed to tell whether anything actually changed, rather than relying on symptom recall? Inflammatory markers, fecal calprotectin, and endoscopic or histologic findings are the measurable options.
  • What is the plan if symptoms improve and the underlying disease does not, or the other way around?

A clinician who answers "there is no human evidence for this yet" is describing the literature accurately, not dismissing the question.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Intestinal inflammation in rodent colitis models
Animal studies only animal

The best-developed claim area. Oral KPV reduced the incidence of DSS- and TNBS-induced colitis in mice with decreased pro-inflammatory cytokine expression; an independent group reported earlier recovery, stronger body weight regain, reduced inflammatory infiltrate, and reduced colonic myeloperoxidase activity in DSS colitis and in CD45RB-high transfer colitis. A rat TNBS model using a stabilizing hydrogel reported the same direction of effect. Consistent, replicated, and entirely in rodents.

[4] [5] [10]

PepT1-mediated uptake as the proposed mechanism
Animal studies only animal

KPV is transported into intestinal epithelial and immune cells by PepT1, a di/tripeptide transporter normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. Uptake kinetics were characterized with radiolabelled peptide and competition experiments. This is a genuinely well-specified mechanism by the standards of this category, established in cell lines and mice.

[4] [8]

Anti-inflammatory signalling independent of melanocortin receptors
Animal studies only animal · review · in vitro

KPV is the C-terminal tripeptide of alpha-MSH, and reviews attribute most of the parent hormone's anti-inflammatory activity to it. Mice expressing a nonfunctional melanocortin-1 receptor still responded to KPV during DSS colitis, which argues the effect is at least partly independent of MC1R signalling. Cell work in human keratinocytes found that neither alpha-MSH nor KPV elevated cyclic AMP, but both produced rapid intracellular calcium responses under specific conditions. The signalling picture is not simple.

[5] [3] [2]

Colitis-associated cancer in mice
Animal studies only animal

In a mouse model of colitis-associated cancer induced with AOM/DSS, PepT1 played a critical role in promoting tumorigenesis, and KPV delivered through that transporter produced therapeutic benefit. Read carefully: this is a mouse chemical-carcinogenesis model, and the same paper is the reason the transporter itself belongs in the safety discussion.

[8]

Oral delivery and formulation dependence
Animal studies only animal

Later work is largely about getting the peptide where it needs to go. Hyaluronic-acid-functionalized nanoparticles carrying KPV, encapsulated in a chitosan/alginate hydrogel, prevented mucosal damage and downregulated TNF-alpha more effectively than untargeted KPV nanoparticles in a mouse colitis model; a self-cross-linked polyglutamic acid hydrogel was built for the same purpose in rats. The recurring implication is that free peptide is not the optimized form.

[9] [10]

Skin and keratinocyte activity
Animal studies only in vitro · review

Human keratinocyte work showed that KPV and its D-isomer produced rapid, acute intracellular calcium responses across a wide concentration range, and that MC1-receptor-transfected cells responded to the tripeptides. Cell culture only; no controlled study of topical or systemic KPV for any skin condition in humans is available.

[2] [3]

Antimicrobial activity
Animal studies only in vitro

alpha-MSH and its C-terminal tripeptide inhibited Staphylococcus aureus colony formation and reduced viability and germ tube formation of Candida albicans in culture, with effects observed down to picomolar concentrations and evidence implicating cyclic AMP in the killing activity. In vitro only.

[1]

Clinical efficacy for any indication in humans
Anecdotal reports only review

No published trial, randomized or uncontrolled, has evaluated KPV in humans for inflammatory bowel disease, skin disease, or anything else. Reviews spanning fifteen years describe the tripeptide as a candidate suitable for future development and continue to describe it that way, which is itself informative.

[6] [11] [7]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • The foundational mouse study in DSS- and TNBS-induced colitis, with the peptide supplied orally in drinking water; the accompanying cell work establishes the concentration at which activity appears

    Reported as oral administration in drinking water. In human intestinal epithelial and T cell lines, inhibition of NF-kappaB and MAP kinase signalling was observed at nanomolar concentrations. [4]

  • Mouse ulcerative-colitis model using orally delivered KPV encapsulated in hyaluronic-acid-functionalized polymeric nanoparticles within a chitosan/alginate hydrogel

    The variable under study is formulation rather than dose. The targeted carrier outperformed untargeted KPV nanoparticles, which is the paper's finding. No free-peptide dose equivalent is established. [9]

  • Human use, any indication, any route

    No dose is established. No published human trial of KPV exists, so there is no human range to report. Reviews position the tripeptide as a candidate for future development rather than as a characterized therapy. [6] [11]

The rodent evidence is oral and, in the later studies, formulation-dependent. Nothing in the published literature establishes a human dose, a route, or a schedule for KPV, and community-typical figures have no citation behind them.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No established human safety profile

    Not established · Unknown. That is an absence of data, not a finding of safety. Reviews describe KPV as an attractive candidate for future treatment of immune-mediated inflammatory disease; that is a statement about promise, not about a safety database. No clinical trial has characterized what the tripeptide does in a person.

    [6] [11]

  • Immunosuppressive mechanism by design

    Consistently reported across the preclinical literature · Not an adverse effect in itself. The point of the molecule is inhibition of NF-kappaB activation, MAP kinase signalling, adhesion molecule and chemokine receptor expression, and pro-inflammatory cytokine production. What sustained blunting of those pathways means for infection risk, wound response, or immune surveillance in a person has never been studied. Immunosuppressive medication, active infection, or a history of malignancy are reasons to raise this with a clinician before considering anything.

    [4] [7]

  • Absence of the pigmentary effect that limits the parent hormone

    Reported consistently; it is the stated rationale for developing the tripeptide instead of alpha-MSH · Generally framed as an advantage rather than a risk: alpha-MSH carries a pigmentary action that limits its use in inflammatory disease, and the C-terminal tripeptide is described as retaining anti-inflammatory activity without it. Worth knowing that this is a characterization from review articles, not an endpoint measured in a human trial.

    [6] [3]

  • Antimicrobial activity and unstudied microbiome effects

    Reported in vitro against Staphylococcus aureus and Candida albicans · alpha-MSH peptides including KPV inhibited S. aureus colony formation and reduced viability and germ tube formation of C. albicans across a broad concentration range in culture. Whether a peptide with direct antimicrobial activity, delivered into the gut, perturbs the intestinal microbiome is an obvious question that the published record does not answer.

    [1]

  • Dependence on a transporter that is itself implicated in disease

    Mechanistic, reported in mouse models · KPV enters cells through PepT1, a di/tripeptide transporter expressed at low levels in the healthy colon and upregulated during intestinal inflammation, so uptake is greatest where inflammation is greatest. The same transporter has been shown to promote colitis-associated cancer in mice, which makes the biology surrounding this peptide more complicated than "anti-inflammatory tripeptide" suggests.

    [4] [8]

  • Unverified identity and purity of unapproved material

    Not quantified · With no approved manufacturer, nothing about the composition, concentration, or contaminant profile of material labeled "KPV" is regulated or independently guaranteed. This is a category-level risk sitting on top of whatever the molecule itself does.

    [11]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Lyophilized short peptides are conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for long-term holding. Reviews of the melanocortin tripeptides note their favorable physicochemical properties relative to the parent hormone as an argument for developability, but no published stability study establishes a shelf life for KPV powder in a vial, and there is no approved manufacturer, no label, and no assigned beyond-use date behind any storage claim.
Reconstituted storage
Once in solution, peptides are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. No published source establishes a solution shelf life for KPV. Note that most of the rodent work delivered the peptide orally, in drinking water or encapsulated in nanoparticles and hydrogels, rather than from a reconstituted vial. The published record therefore says nothing about how an injectable solution behaves.
Reconstitution diluent
Bacteriostatic water is the conventional diluent for lyophilized research peptides, including this one; it is sterile water preserved with 0.9% benzyl alcohol. Sterile water without a preservative is used where a preservative is contraindicated and is treated as single-use.
Reconstitution & handling
Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let it dissolve on its own. Swirl gently if needed; never shake. A properly reconstituted solution is clear; anything cloudy, discolored, or carrying visible particulate is discarded. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
A recurring theme in the delivery literature is that free KPV is not especially good at reaching inflamed intestinal tissue on its own, which is why several groups built targeted carriers for it. Treat "small peptide, therefore robust" as an assumption rather than a finding.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include KPV

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

  • Gut Healing

    A research reference for the peptides mapped to gut healing and intestinal repair. It covers what the rodent colitis literature established, why almost none of it has been tested in people, and what "healing the gut lining" does and does not mean in the published record.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

11 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder